Search Results

Surface Oncology, Inc. announced that both Institutional Shareholder Services and Glass, Lewis & Co. have recommended Surface stockholders vote “FOR” the adoption of Surface’s merger agreement with Coherus BioSciences, Inc.

MyMD Pharmaceuticals, Inc. today announced the appointment of Mitchell Glass, M.D., a member of the board of directors of the Company, as president and chief medical officer.

Zevra Therapeutics, Inc. announced that leading proxy advisory firms Institutional Shareholder Services and Glass Lewis & Co. have voiced their support for Zevra’s nominees and strategy and found that Mangless’ arguments and nominees were not compelling.

Ardelyx, Inc. announced that leading proxy advisory firms Institutional Shareholder Services Inc. and Glass Lewis & Co have recommended that Ardelyx stockholders vote “FOR” the Company’s proposal to amend the Company’s certificate of incorporation to increase Ardelyx’s authorized shares of common stock from 300 million to 500 million shares.

Alkermes plc announced that leading proxy advisory firm Glass, Lewis & Co. has recommended that Alkermes shareholders vote the WHITE proxy card “FOR” all seven of Alkermes’ highly qualified director nominees at the Company’s upcoming 2023 Annual General Meeting of Shareholders, which is scheduled to be held on June 29, 2023.

Aurinia Pharmaceuticals Inc. announced that Glass Lewis & Co., a leading independent proxy advisor, has recommended that Aurinia shareholders vote FOR ALL proposals at the Company’s 2023 Annual General Meeting, including the re-election to the Board of Directors of all eight incumbent directors and the approval of the Company’s say-on-pay resolution.

Thrive Bioscience, Inc. is pleased to announce that Todd Lewis has joined the executive management team as its Chief Commercial Officer.

Cumulus Oncology, Europe’s first oncology-focused biotech company creation factory, announces the appointment of Catherine Lewis La Torre to its Board of Directors.